10 Participants Needed

Exercise for Pulmonary Arterial Hypertension

CE
Overseen ByClaire E Child, DPT, MPH
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: University of Washington
Must be taking: PAH medications
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial requires that you continue taking your current medications for pulmonary arterial hypertension (PAH) throughout the study.

What data supports the effectiveness of the treatment Home exercise program for Pulmonary Arterial Hypertension?

Research shows that both home-based and supervised exercise programs can improve exercise capacity, quality of life, and symptoms in patients with pulmonary arterial hypertension. Although most studies focus on supervised programs, home-based exercise has also been shown to have positive effects on function and quality of life.12345

Is exercise safe for people with pulmonary arterial hypertension?

Research shows that exercise programs, when carefully supervised and monitored, are generally safe for people with pulmonary arterial hypertension. Studies have reported improvements in symptoms and quality of life without significant adverse events.36789

How does the home exercise program treatment for pulmonary arterial hypertension differ from other treatments?

The home exercise program for pulmonary arterial hypertension is unique because it focuses on individually tailored exercises that patients can do at home, improving their exercise capacity and daily physical activity. Unlike traditional medical treatments, this approach emphasizes rehabilitation and long-term care, offering a new way to enhance quality of life and functional capacity for patients.310111213

What is the purpose of this trial?

Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention period where patients will receive complimentary sotatercept as prescribed, plus a tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring.

Research Team

MB

Mary Beth Brown, PT, PhD

Principal Investigator

University of Washington

Eligibility Criteria

This trial is for adults over 18 with Pulmonary Arterial Hypertension (PAH) who are stable on PAH therapy for more than 90 days and need to start sotatercept treatment. Participants must be able to follow the study schedule, consent to it, and engage in a home exercise program. Excluded are those with other types of pulmonary hypertension, certain heart conditions, uncontrolled high blood pressure, recent serious cardiovascular events or procedures.

Inclusion Criteria

Baseline RHC documenting minimum PVR of ≥ 5 WU and PCWP or left ventricular end-diastolic pressure of ≤ 15 mmHg
Ability to adhere to study visit schedule and understand and comply with all protocol requirements
Ability to understand and provide written informed consent
See 5 more

Exclusion Criteria

My condition is classified under PH WHO Groups 2, 3, 4, or 5.
Baseline platelet count < 50,000/mm3
Pregnant or breastfeeding females
See 13 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive sotatercept therapy and engage in a tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring

24 weeks
Baseline and final in-person visits, remote monitoring at two interim assessment timepoints

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Long-term follow-up

Measurement fidelity for the innovative 'remote Six Minute Walk Test (6MWT)'

18 months

Treatment Details

Interventions

  • Home exercise program
Trial Overview The study tests a combination of sotatercept medication and a tailored home exercise program monitored remotely using fitness trackers and oxygen saturation devices over 24 weeks. The aim is to see how this combined approach affects patients with PAH.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Exercise ArmExperimental Treatment1 Intervention
Patients with PAH on sotatercept plus a tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Washington

Lead Sponsor

Trials
1,858
Recruited
2,023,000+

Findings from Research

A 12-week text message-based intervention significantly increased daily step counts in patients with pulmonary arterial hypertension (PAH), with an average increase of 1,409 steps compared to a decrease of 149 steps in the control group.
The intervention also led to improvements in quality of life and reductions in visceral fat, suggesting that mobile health strategies can effectively promote physical activity in PAH patients, although no significant change was observed in the six-minute walk test.
A Mobile Health Intervention to Increase Physical Activity in Pulmonary Arterial Hypertension.Hemnes, AR., Silverman-Lloyd, LG., Huang, S., et al.[2022]
In a study of 30 patients with pulmonary arterial hypertension (PAH), both hospital-based and home-based cardiopulmonary rehabilitation programs did not show significant improvements in functional status, quality of life, depression severity, or hemodynamic parameters after eight weeks.
The findings suggest that short-term cardiopulmonary rehabilitation may not be effective for patients with PAH, indicating a need for longer rehabilitation programs to potentially achieve better outcomes.
Effects of cardiopulmonary rehabilitation on pulmonary arterial hypertension: A prospective, randomized study.Karapolat, H., Çınar, ME., Tanıgör, G., et al.[2022]
A specialized exercise training and rehabilitation program is recommended as an effective add-on treatment for patients with pulmonary arterial hypertension, showing significant improvements in symptoms, exercise capacity, and quality of life across over 470 patients in various studies.
The safety profile of these exercise programs is acceptable, with some studies indicating excellent survival rates over 1 to 2 years, although most studies had small sample sizes and were not designed to measure long-term clinical outcomes.
Principles of rehabilitation and reactivation: pulmonary hypertension.Marra, AM., Egenlauf, B., Bossone, E., et al.[2015]

References

A Mobile Health Intervention to Increase Physical Activity in Pulmonary Arterial Hypertension. [2022]
Effects of cardiopulmonary rehabilitation on pulmonary arterial hypertension: A prospective, randomized study. [2022]
Principles of rehabilitation and reactivation: pulmonary hypertension. [2015]
Effects of home-based exercise training on functional outcomes and quality of life in patients with pulmonary hypertension: A randomized clinical trial. [2020]
Exercise training in patients with pulmonary arterial hypertension: a case report. [2021]
Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. [2022]
The exercise in pulmonary arterial hypertension (ExPAH) study: A randomized controlled pilot of exercise training and multidisciplinary rehabilitation in pulmonary arterial hypertension. [2022]
Short term effects of exercise training on exercise capacity and quality of life in patients with pulmonary arterial hypertension: protocol for a randomised controlled trial. [2021]
Exercise training and rehabilitation in pulmonary arterial hypertension: rationale and current data evaluation. [2014]
Individually tailored home-based physiotherapy program makes sustainable improvement in exercise capacity and daily physical activity in patients with pulmonary arterial hypertension. [2022]
A review of ongoing trials in exercise based rehabilitation for pulmonary arterial hypertension. [2023]
12.United Statespubmed.ncbi.nlm.nih.gov
Home Exercise Training in Children and Adolescents with Pulmonary Arterial Hypertension: A Pilot Study. [2018]
13.United Statespubmed.ncbi.nlm.nih.gov
Rationale and Design of a Randomized Controlled Trial Evaluating Whole Muscle Exercise Training Effects in Outpatients with Pulmonary Arterial Hypertension (WHOLEi+12). [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security